Literature DB >> 25881797

Intoxications by the dissociative new psychoactive substances diphenidine and methoxphenidine.

Anders Helander1, Olof Beck, Matilda Bäckberg.   

Abstract

BACKGROUND: Diphenidine (1-(1,2-diphenylethyl)piperidine) and its 2-methoxylated derivative methoxphenidine (MXP, 2-MeO-diphenidine) are substances with dissociative effects that were recently introduced for "recreational" purpose through the online-based sale of new psychoactive substances (NPS). A number of analytically confirmed non-fatal intoxications associated with diphenidine or MXP have occurred in Sweden and were included in the STRIDA project. STUDY
DESIGN: Observational case series of consecutive patients with admitted or suspected intake of NPS and requiring intensive treatment in an emergency room and hospitalization in Sweden. PATIENTS AND METHODS: Blood and urine samples were collected from intoxicated patients presenting at emergency departments all over the country. NPS analysis was performed by multi-component liquid chromatography-mass spectrometry methods. Data on clinical features were collected during telephone consultations with the Poisons Information Centre and retrieved from medical records. Information was also obtained from online drug discussion forums. CASE SERIES: Over a 12-month period from January to December 2014, 750 cases of suspected NPS intoxication originating from emergency departments were enrolled in the STRIDA project of which 14 (1.9%) tested positive for diphenidine and 3 (0.4%) tested positive for MXP. Co-exposure to several other NPS (e.g., 5-/6-(2-aminopropyl)benzofuran, 2-4-bromomethcathinone, butylone, 3,4-dichloromethylphenidate, 5-methoxy-N-isopropyltryptamine, methiopropamine, and α-pyrrolidinopentiothiophenone), also including other dissociative substances (3-/4-methoxyphencyclidine), and classical drugs of abuse (e.g., cannabis and ethanol) was documented in 87% of these cases. The 17 patients were aged 20-48 (median: 32) years, and 13 (76%) were men. They commonly presented with hypertension (76%), tachycardia (47%), anxiety (65%), and altered mental status (65%) including confusion, disorientation, dissociation, and/or hallucinations. Eight patients (47%) displayed severe intoxication (Poisoning Severity Score 3). The diphenidine- or MXP-positive patients required hospitalization for 1-3 (median: 2) days. In addition to standard supportive therapy, half of the cases were treated with benzodiazepines and/or propofol.
CONCLUSION: The adverse effects noted in analytically confirmed cases of NPS intoxication involving diphenidine or MXP were similar to those reported for other dissociative substances such as ketamine and methoxetamine. However, the high proportion of polysubstance use might have played a role in the intoxication and clinical features in some cases.

Entities:  

Keywords:  Diphenidine; Dissociative drugs; LC–MS; Legal highs; Methoxphenidine; NMDA receptor antagonist; New psychoactive substance; Research chemicals; STRIDA project; Severe adverse events

Mesh:

Substances:

Year:  2015        PMID: 25881797     DOI: 10.3109/15563650.2015.1033630

Source DB:  PubMed          Journal:  Clin Toxicol (Phila)        ISSN: 1556-3650            Impact factor:   4.467


  10 in total

1.  A methoxydiphenidine-impaired driver.

Authors:  Nicole Stachel; Andrea Jacobsen-Bauer; Gisela Skopp
Journal:  Int J Legal Med       Date:  2015-10-19       Impact factor: 2.686

2.  The Poisoning Severity Score: If It Did Not Exist, We Would Have To Invent It.

Authors:  Rose Cairns; Nicholas A Buckley
Journal:  J Med Toxicol       Date:  2017-05-17

Review 3.  When good times go bad: managing 'legal high' complications in the emergency department.

Authors:  Charles R Caffrey; Patrick M Lank
Journal:  Open Access Emerg Med       Date:  2017-12-20

4.  Drug trends and harm related to new psychoactive substances (NPS) in Sweden from 2010 to 2016: Experiences from the STRIDA project.

Authors:  Anders Helander; Matilda Bäckberg; Olof Beck
Journal:  PLoS One       Date:  2020-04-23       Impact factor: 3.240

5.  Intriguing Cytotoxicity of the Street Dissociative Anesthetic Methoxphenidine: Unexpected Impurities Spotted.

Authors:  Bronislav Jurásek; Silvie Rimpelová; Martin Babor; Jan Čejka; Vilém Bartůněk; Martin Kuchař
Journal:  Int J Mol Sci       Date:  2022-02-14       Impact factor: 5.923

Review 6.  A review of synthetic cathinones emerging in recent years (2019-2022).

Authors:  Patryk Kuropka; Marcin Zawadzki; Paweł Szpot
Journal:  Forensic Toxicol       Date:  2022-09-15       Impact factor: 2.541

7.  Pharmacological Investigations of the Dissociative 'Legal Highs' Diphenidine, Methoxphenidine and Analogues.

Authors:  Jason Wallach; Heather Kang; Tristan Colestock; Hamilton Morris; Zuner A Bortolotto; Graham L Collingridge; David Lodge; Adam L Halberstadt; Simon D Brandt; Adeboye Adejare
Journal:  PLoS One       Date:  2016-06-17       Impact factor: 3.240

8.  Characteristics of NPS use in patients admitted to acute psychiatric services in Southeast Scotland: a retrospective cross-sectional analysis following public health interventions.

Authors:  Kyle H Bennett; Helen M Hare; Robert M Waller; Helen L Alderson; Stephen Lawrie
Journal:  BMJ Open       Date:  2017-12-03       Impact factor: 2.692

9.  Mechanistic Insights into the Stimulant Properties of Novel Psychoactive Substances (NPS) and Their Discrimination by the Dopamine Transporter-In Silico and In Vitro Exploration of Dissociative Diarylethylamines.

Authors:  Michelle A Sahai; Colin Davidson; Neelakshi Dutta; Jolanta Opacka-Juffry
Journal:  Brain Sci       Date:  2018-04-07

Review 10.  Designer drugs: mechanism of action and adverse effects.

Authors:  Dino Luethi; Matthias E Liechti
Journal:  Arch Toxicol       Date:  2020-04-06       Impact factor: 5.153

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.